Moderna CEO Stephan Bancel recalls he was at a Lebanese restaurant celebrating a friend’s birthday the moment he learned of a cancer vaccine's successful trial
MODERNA SAYS THE FDA HAS APPROVED ITS UPDATED 2026-2027 COVID-19 VACCINES, WITH MNEXSPIKE WINNING FDA APPROVAL FOR ITS NEW FORMULA AND SPIKEVAX RECEIVING APPROVAL FOR THE 2026-2027 FORMULA
Moderna plans to raise $2 billion from selling debt that can be exchanged for shares, which it will use to invest in its cancer vaccine business and to repay debt
MODERNA PLANS TO ISSUE $2 BILLION IN CONVERTIBLE SENIOR NOTES, WITH NET PROCEEDS GOING TO GENERAL CORPORATE PURPOSES AND SOME FOR CAPPED CALL TRANSACTIONS. THEY WILL ALSO OFFER AN OPTION FOR AN ADDITIONAL $300 MILLION OF NOTES.